PATENT CLAIM ANALYSIS

Application Number: 15869268
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["544", "231000"]

Abstract:
The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

Claim (Index 11):
A compound of formula IE according to  claim 10 , selected from the group consisting of\n (4S)-3\u2032-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1\u2032-methyl-spiro[5,6,7,8-tetrahydro-1H-cyclohepta[c]pyrazole-4,6\u2032-hexahydropyrimidine]-2\u2032,4\u2032-dione (4S)-3\u2032-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1,1\u2032-dimethyl-spiro[5,6,7,8-tetrahydrocyclohepta[c]pyrazole-4,6\u2032-hexahydropyrimidine]-2\u2032,4\u2032-dione and (4S)-3\u2032-[2,6-Difluoro-4-(2-phenylethynyl)phenyl]-1\u2032,2-dimethyl-spiro[5,6,7,8-tetrahydrocyclohepta[c]pyrazole-4,6\u2032-hexahydropyrimidine]-2\u2032,4\u2032-dione.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.2
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15245955', '15707848', '15283010', '15205466', '15867097']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8351595385266811
- 35 USC 102 Novelty (BERT): 0.5666015126393641
- Combined Prediction Score: 0.8083037359379495
- Mean Citation Score: 442.562574
- Max Citation Score: 469.8305
- Similarity Product: 366.1446934864224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test